Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Deferred Tax Assets: 2020-2021

Historic Current Deferred Tax Assets for China SXT Pharmaceuticals (SXTC) over the last 2 years, with Mar 2021 value amounting to $547,807.

  • China SXT Pharmaceuticals' Current Deferred Tax Assets fell 4.87% to $504,522 in Q3 2021 from the same period last year, while for Sep 2021 it was $504,522, marking a year-over-year decrease of 4.87%. This contributed to the annual value of $547,807 for FY2021, which is 7.28% up from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Current Deferred Tax Assets stood at $547,807 for FY2021, which was up 7.28% from $510,617 recorded in FY2020.
  • Over the past 5 years, China SXT Pharmaceuticals' Current Deferred Tax Assets peaked at $547,807 during FY2021, and registered a low of $510,617 during FY2020.
  • For the 2-year period, China SXT Pharmaceuticals' Current Deferred Tax Assets averaged around $529,212, with its median value being $529,212 (2020).
  • Data for China SXT Pharmaceuticals' Current Deferred Tax Assets shows a peak YoY climbed of 7.28% (in 2021) over the last 5 years.
  • Yearly analysis of 2 years shows China SXT Pharmaceuticals' Current Deferred Tax Assets stood at $510,617 in 2020, then climbed by 7.28% to $547,807 in 2021.